Vermillion this week announced the appointment of William Wallen to its board, effective upon confirmation of the firm's Chapter 11 reorganization plan.
Wallen is currently chief scientific officer and senior vice president of R&D at Idexx Laboratories. Prior to that, he held several high-level positions at Bayer Healthcare's Diagnostics Division, including his last post as senior vice president, head officer of technology.
He also held leadership roles at Becton Dickinson and Wampole Laboratories, a division of Carter-Wallace.
A hearing on Vermillion's reorganization plan is schedule for Jan. 7, 2010.
Caris Diagnostics this week said that Jonathan Knowles will become vice chairman of its board on Jan. 1, 2010. He joined the company's board on Sept. 1.
Knowles will provide scientific and strategic guidance and support the identification and expansion of Caris' R&D opportunities, the company said. He also will assist in furthering the company's international presence.
Knowles is president of group research at Roche and a member of its corporate executive committee. Recently, he was appointed a professor of translational medicine at Ecole Polytechnique Federale de Lausanne in Switzerland.
Expression Pathology said this week that Jon Burrows has joined the company as vice president of R&D.
He previously held management positions at Ventana, Novartis, Chiron, and Sugen.
In addition, Jenny Heidbrink joined the firm as head of mass spectrometry. She comes from Celera and Lawrence Livermore National Laboratory. And Sheeno Thyparambil joined the company as a "key mass spec scientist," the company said. Thyparambil comes from the University of Arkansas and the US Food and Drug Administration.